Search the Newsreel

Zevra Therapeutics Stock Down — European Panel Slams Arimoclomol Bid for Niemann-Pick Type C

Zevra Therapeutics' stock (ZVRA) dropped following a negative opinion from the European Medicines Agency's CHMP regarding its drug arimoclomol for Niemann-Pick disease type C. The company plans to request a re-examination while continuing to provide patient access through an Expanded Access Program. Despite the …

Zevra Therapeutics Receives EMA Negative Opinion on Arimoclomol Marketing Application

Zevra Therapeutics announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on its Marketing Authorization Application for arimoclomol, a treatment for Niemann-Pick disease type C (NPC). The company plans to request a re-examination of this …

Daybu readthrough in EU? Zevra’s NPC bid flounders

Zevra Therapeutics plans to ask the EMA's CHMP to reconsider its decision regarding arimoclomol for Niemann-Pick disease type C (NPC). This move follows the CHMP's initial ruling that the efficacy for NPC had not been sufficiently proven. Zevra aims to emulate Acadia Pharmaceuticals' success …

ZVRA Stock Slides As Traders Gauge Pullback And Cash Strength

Zevra Therapeutics Inc. (ZVRA) has experienced a significant stock slide, falling over 22% from the mid-$14s to the high-$9s, breaking previous support levels. Despite this sharp pullback, the company maintains a strong financial position with minimal debt and over $95M in cash, although much …

Zevra down on EU snub for rare disease therapy (ZVRA:NASDAQ)

Zevra Therapeutics (ZVRA) shares dropped approximately 30% in premarket trading after an expert panel of the EU drug regulator declined to endorse its lead product, arimoclomol, for Niemann-Pick disease type C. This rare neurodegenerative condition is the target for the therapy, which failed to …

Zevra Therapeutics to Seek Re-Examination After Negative CHMP Opinion on Arimoclomol for NPC

Zevra Therapeutics announced that the European Medicines Agency's CHMP issued a negative opinion regarding its Marketing Authorization Application for arimoclomol, a treatment for Niemann-Pick disease type C (NPC). Despite this setback, Zevra plans to request a re-examination, reaffirming its commitment to bringing the drug …

After Negative EU Opinion, Zevra Supports Access for Eligible Patients

Zevra Therapeutics received a negative opinion from the European Medicines Agency’s CHMP regarding its Marketing Authorization Application for arimoclomol to treat Niemann-Pick disease type C (NPC) in the EU. Despite this setback, the company plans to request a re-examination and continues to provide arimoclomol …

Zevra Therapeutics Provides Update on Regulatory Submission

Zevra Therapeutics announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on their Marketing Authorization Application for arimoclomol, a treatment for Niemann-Pick disease type C (NPC). Despite this setback, the company plans to request a …

ZVRA Stock Sinks 23% On EU Setback — Analyst Says Risk Is ‘A Headwind, But Not Insurmountable’

ZeVra Therapeutics jumps 29% as Miplyffa patent gains FDA exclusivity through 2041

ZeVra Therapeutics shares rose 29% after its drug Miplyffa received FDA patent exclusivity until 2041 for Niemann-Pick Disease Type C. The company reported strong financial results for FY25, including profitability, debt retirement, and significant cash reserves. With an innovative pipeline and attractive valuation, ZeVra …

Vera Bradley Enhances Executive Severance and Retention Protections

Vera Bradley (VRA) has implemented new Executive Severance Plan Agreements for its COO/CFO Martin Layding and CBO Melinda Paraie. These agreements provide severance benefits and retention incentives, including salary, bonuses, COBRA payments, and accelerated stock vesting, contingent on non-compete and confidentiality clauses. This move …

Zevra’s Aug. 5 results webcast will be replayed for 90 days

Zevra Therapeutics (NasdaqGS: ZVRA) announced it will release its Q2 2026 corporate and financial results on Wednesday, August 5, 2026, after market close, followed by a conference call and audio webcast at 4:30 p.m. ET. A replay of the webcast will be available for …

Zevra Therapeutics Announces Date for Second Quarter 2026 Financial Results Conference Call

Zevra Therapeutics announced it will release its second quarter 2026 corporate and financial results on August 5, 2026, followed by a conference call and audio webcast at 4:30 p.m. ET. The company, which focuses on developing therapies for rare diseases, highlighted its commitment to …

Elevra Lithium (ASX: ELV) Falls — Can the Stock Break Out of Its Volatile Cycle?

ZVRA - Zevra Therapeutics: Galloping Through a Green Safari

Zevra Therapeutics has successfully transitioned from a prodrug company to a rare disease powerhouse, marked by the FDA approval of MIPLYFFA for Niemann-Pick disease Type C and a $100 million sale of a Rare Pediatric Disease Priority Review Voucher. The company's financial standing is …

Elevra Lithium (ASX:ELV) Posts A$226.83M Revenue—Can It Capitalise on Next Lithium Recovery?

Vera Bradley (VRA) Q2 2026 Earnings: EPS Surprise of 73% on Better-Than-Expected Bottom Line, but Stock Slides

Vera Bradley Is Slowly Turning The Ship Around, But It's Not Enough (Rating Downgrade)

Vraj Iron promoters hold 24.7M shares with no encumbrance in FY26

Price to earnings forward of Elevra Lithium Limited – ASX:ELV

Elevra Lithium (ASX:ELV): Can This Lithium Stock Survive the Sector Shakeout?

Elevra Lithium (ASX:ELV): Lithium Stock Slides as Battery Metals Pressure Continues

Ian Bickley Bought 2.4% More Shares In Vera Bradley

Vera Bradley posts first quarterly revenue growth since fiscal 2022

Vera Bradley earnings missed by $0.26, revenue fell short of estimates

VERA BRADLEY ($VRA) Releases Q1 2027 Earnings

Vera Bradley Announces First Quarter Fiscal Year 2027 Results

Vera Bradley Q1 Earnings Call Highlights

Vera Bradley (VRA) Reports Q1 Loss, Tops Revenue Estimates

Vera Bradley Stock Jumps After Q1 Double Beat — First Revenue Growth in Four Years - Vera Bradley (NASDAQ

Why Vraj Iron and Steel's (NSE:VRAJ) Shaky Earnings Are Just The Beginning Of Its Problems

Vraj Iron FY26 net profit falls 29.4% to ₹295.27 million

Vraj Iron & Steel consolidated net profit rises 55.54% in the March 2026 quarter

Vera Bradley schedules June 11 call on first‑quarter FY 2027 results

Vera Bradley, Inc. Announces Reporting Date for First Quarter Fiscal Year 2027 Results

Elevra Lithium (ASX:ELV) Stock Falls on Friday as Lithium Equities Cool Again